Eukles Asset Management’s ResMed RMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.66M | Sell |
18,756
-657
| -3% | -$136K | 1.51% | 22 |
|
|
2026
Q1 | $4.36M | Sell |
19,413
-3,323
| -15% | -$828K | 1.94% | 14 |
|
|
2025
Q4 | $5.48M | Sell |
22,736
-129
| -0.6% | -$33K | 2.13% | 11 |
|
|
2025
Q3 | $6.26M | Sell |
22,865
-73
| -0.3% | -$19.9K | 2.44% | 9 |
|
|
2025
Q2 | $5.92M | Buy |
22,938
+43
| +0.2% | +$10.3K | 2.42% | 8 |
|
|
2025
Q1 | $5.13M | Buy |
22,895
+562
| +3% | +$131K | 2.25% | 10 |
|
|
2024
Q4 | $5.11M | Sell |
22,333
-933
| -4% | -$225K | 2.18% | 10 |
|
|
2024
Q3 | $5.68M | Sell |
23,266
-89
| -0.4% | -$19.9K | 2.28% | 11 |
|
|
2024
Q2 | $4.47M | Buy |
23,355
+87
| +0.4% | +$17.7K | 1.93% | 12 |
|
|
2024
Q1 | $4.61M | Buy |
23,268
+895
| +4% | +$164K | 2% | 11 |
|
|
2023
Q4 | $3.85M | Buy |
22,373
+10
| +0% | +$1.54K | 1.82% | 17 |
|
|
2023
Q3 | $3.31M | Buy |
22,363
+270
| +1% | +$48.8K | 1.75% | 18 |
|
|
2023
Q2 | $4.83M | Buy |
22,093
+172
| +0.8% | +$38.3K | 2.47% | 7 |
|
|
2023
Q1 | $4.8M | Sell |
21,921
-84
| -0.4% | -$18.2K | 2.61% | 7 |
|
|
2022
Q4 | $4.58M | Buy |
22,005
+429
| +2% | +$94.3K | 2.67% | 6 |
|
|
2022
Q3 | $4.71M | Sell |
21,576
-17
| -0.1% | -$3.87K | 3.09% | 4 |
|
|
2022
Q2 | $4.53M | Buy |
21,593
+143
| +0.7% | +$30.4K | 2.87% | 5 |
|
|
2022
Q1 | $5.2M | Sell |
21,450
-569
| -3% | -$138K | 2.83% | 6 |
|
|
2021
Q4 | $5.74M | Buy |
22,019
+268
| +1% | +$69.5K | 2.78% | 5 |
|
|
2021
Q3 | $5.73M | Buy |
21,751
+1,176
| +6% | +$322K | 3.14% | 4 |
|
|
2021
Q2 | $5.07M | Buy |
20,575
+1,354
| +7% | +$285K | 2.81% | 4 |
|
|
2021
Q1 | $3.73M | Buy |
19,221
+780
| +4% | +$156K | 2.41% | 10 |
|
|
2020
Q4 | $3.92M | Buy |
18,441
+323
| +2% | +$64.4K | 2.71% | 6 |
|
|
2020
Q3 | $3.11M | Buy |
18,118
+174
| +1% | +$32.1K | 2.42% | 10 |
|
|
2020
Q2 | $3.44M | Buy |
17,944
+711
| +4% | +$116K | 2.93% | 4 |
|
|
2020
Q1 | $2.54M | Sell |
17,233
-754
| -4% | -$120K | 2.64% | 8 |
|
|
2019
Q4 | $2.79M | Sell |
17,987
-85
| -0.5% | -$12.3K | 2.27% | 11 |
|
|
2019
Q3 | $2.44M | Sell |
18,072
-34
| -0.2% | -$4.46K | 2.12% | 12 |
|
|
2019
Q2 | $2.21M | Sell |
18,106
-71
| -0.4% | -$7.87K | 1.92% | 15 |
|
|
2019
Q1 | $1.89M | Buy |
18,177
+145
| +0.8% | +$15K | 1.72% | 18 |
|
|
2018
Q4 | $2.05M | Buy |
+18,032
| New | +$1.93M | 2.14% | 12 |
|
Other funds holding RMD
Eukles Asset Management's RMD Position: Q2 2026 in Review
Eukles Asset Management reduced its ResMed (RMD) stake by 3.4% in Q2 2026, selling an estimated $136K and leaving 18,756 shares worth $3.66M. The position accounts for 1.51% of the portfolio, ranked #22.
Eukles Asset Management first reported a position in RMD in Q4 2018 and has held it in 31 quarters since. The position peaked at $6.26M in Q3 2025. 891 funds tracked by Wall St. Rank hold RMD as of Q2 2026.
- Eukles Asset Management held 18,756 shares of ResMed worth $3.66M as of Q2 2026.
- Eukles Asset Management sold 657 ResMed shares in Q2 2026, an estimated $136K.
- ResMed made up 1.51% of Eukles Asset Management's portfolio in Q2 2026, its #22 holding.
- Eukles Asset Management first reported a position in ResMed in Q4 2018 and has held it in 31 quarters since.
- Eukles Asset Management's ResMed position peaked at $6.26M in Q3 2025.
- 891 funds tracked by Wall St. Rank held ResMed as of Q2 2026.
Based on Eukles Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.